Catalent (NYSE:CTLT) Rating Lowered to Sell at StockNews.com

Catalent (NYSE:CTLT) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday.

A number of other brokerages also recently issued reports on CTLT. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $63.40.

Catalent Stock Up 2.2 %

NYSE CTLT opened at $60.98 on Friday. The company has a fifty day moving average of $59.81 and a two-hundred day moving average of $58.29. The firm has a market capitalization of $11.07 billion, a price-to-earnings ratio of -26.98, a PEG ratio of 2.37 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent has a 52 week low of $36.74 and a 52 week high of $61.50.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) earnings per share. On average, analysts predict that Catalent will post 0.84 earnings per share for the current year.

Insider Buying and Selling at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 over the last quarter. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Catalent

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after buying an additional 1,169,044 shares in the last quarter. National Bank of Canada FI increased its position in Catalent by 300.0% during the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock worth $88,481,000 after buying an additional 1,095,578 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Catalent by 166.5% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after purchasing an additional 863,624 shares during the period. Finally, ING Groep NV grew its position in shares of Catalent by 162.5% in the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after purchasing an additional 699,851 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.